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• Genetic abnormalities such as deletions in IKZF1 (70%), PAX5
(35%), and CDKN2A/2B (30%) detected in Philadelphia 
chromosome-positive (Ph+) B-ALL.1)
• Ph+ B-ALL patients with IKZF1 deletion have poor prognosis 
when treated with imatinib- or dasatinib-based regimens.2)
• ‘IKZF1plus’  (IKZF1 deletion with additional co-occurring 
deletion(s)) was also shown to be prognostic in GIMEMA-led 
trials (dasatinib plus blinatumomab). 3)
• The molecular determinants for clinical outcomes in ponatinib-
treated patients remain unknown. 
We systematically analyzed genetic alterations in adult Ph+ B-ALL 
patients treated with Hyper-CVAD plus dasatinib,4) Hyper-CMAD 
plus dasatinb,4) or Hyper-CVAD plus ponatinib5) and investigated 
the prognostic significance of the genetic alterations. 
Aim
IKZF1plus status was an independent prognostic 
factor for outcome in patients with Ph+ B-ALL 
treated with Hyper-CVAD plus ponatinib. In 
contrast, in patients treated with dasatinib-based 
regimen, the outcomes were poor across all 
molecular subsets. 
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Figure 1. CONSORT diagram.
Figure 2. 
Landscape of genetic alterations in 105 cases of Ph+ B-ALL. 
Figure 3. 
Co-occurrence and exclusiveness  
of each genetic alteration.
Results
Figure 4. Impact of clinical features and genetic 
alterations on overall survival.
Figure 5A, B. Impact of IKZF1 status.
Figure 6A, B. Impact of IKZF1 status in each cohort (A; ponatinib, B; dasatinib).
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